Magic mushrooms and mood: exploring Psilocybin as a depression treatment
Journal of the Pakistan Medical Association – December 20, 2025
Source: OpenAlex
Summary
A significant development in Psychiatry: Psilocybin, a potent hallucinogen, is emerging as a viable treatment for Major Depressive Disorder. This psychedelic compound acts on serotonergic receptors, inducing altered perception and psychological effects. Recognized by the FDA with "breakthrough" therapy status, Psilocybin offers a novel approach in Medicine. Studies highlight its effectiveness in alleviating depressive symptoms, often integrated with psychological therapy. Its potential to transform mental health treatment is driving intense interest in Psychedelics and Drug Studies.
Abstract
Dear Editor, In view of ongoing global research on mental health, especially Major Depressive Disorder, we would like to draw attention to a psychedelic substance, Psilocybin, which has been emerging as a viable treatment option for MDD. Psilocybin is a psychedelic compound derived from certain mushrooms that acts on Serotonergic receptors (primarily 5HT-2A). Psychedelic substances have psychological effects, i.e., hallucinations, euphoria, and altered perception (1). Studies have demonstrated their effectiveness in the treatment of disorders like ‘Major Depressive Disorder (MDD)’, and ‘Treatment-Resistant Depression’. Recently, the FDA gave ‘breakthrough’ therapy status to a psilocybin treatment developed by London-based biotechnology company ‘Compass Pathways Ltd’ as stated in (2).